Media Advisory: Surescripts to Present on Innovative Interoperability at 2025 Nourishing Change Conference Hosted by Kroger Health, May 13-15
'I can't wait to join industry leaders at the 2025 Nourishing Change Conference to share insights & discuss how we can focus on innovations that make a meaningful difference for patients," said Melanie Marcus, Chief Marketing & Customer Experience Officer.
Share
'I can't wait to join industry leaders as part of a panel at the 2025 Nourishing Change Conference to share insights and discuss how we can continue to focus on innovations that make a meaningful difference for patients and the people who serve them,' said Melanie Marcus, Chief Marketing and Customer Experience Officer for Surescripts.
'Healthcare is facing serious challenges, from provider burnout to patients not being able to access or afford care. It's a challenge that collaboration and innovation that advances health intelligence sharing can help solve. When clinicians and care providers are better informed, it accelerates decisions, keeping patient care on track," added Marcus.
To learn more, check out the panel discussion:
What Does Optimal Interoperability Look Like?
When: May 14, 2025, 2:00-3:15PM
Location: Breakout Sessions--Part One
Overview: What would it take for every part of the health system to connect and communicate? This session explores the path to true interoperability—what it looks like in practice, where it's already working, and how we expand its impact across every community.
Panelists: Melanie Marcus, Surescripts, Yousuf Ahmad, AssureCare, David Pope, XiFin Pharmacy Solutions and moderator, Elizabeth Koonin, UnitedHealthcare.
Background:
In 2024, Surescripts supported 27.2 billion exchanges of patient clinical and benefit information, enabling 2.29 million healthcare professionals and organizations with access to clinical and benefit information for virtually every insured American.
Health intelligence sharing at scale is helping to increase patient safety, lower costs and improve the quality of care by enabling:
2.6 billion electronic prescriptions to be delivered in 2024, helping patients get needed medications faster and safer.
Nearly 900,000 prescribers with technology like Real-Time Prescription Benefit to saving patients an average of $82 per prescription and more than $1,000 per specialty medication.
Touchless Prior Authorization, improving efficiency for care providers and reducing the average time to approve a prior authorization from more than one hour to just 34 seconds, helping patients get needed medications faster.
For more information about how Surescripts is helping improve healthcare for patients and the people who serve them, check out Surescripts 2024 Annual Impact Report.
About Surescripts
Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we bring healthcare together to inform and accelerate decisions, helping keep patient care on track. With the Surescripts Network Alliance®, we're empowering the healthcare ecosystem with intelligence and interoperability for smarter, faster prescribing, prior authorization, treatment, care management and more. Visit us at surescripts.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
40 minutes ago
- Fox News
RFK Jr., Hegseth face-off in impressive pullup, pushup Pentagon showdown
FIRST ON FOX: Secretary of Health and Human Services Robert F. Kennedy Jr. visited the Department of Defense to challenge Secretary Pete Hegseth to a pullup and pushup competition, dubbed the "Pete and Bobby challenge," as the Trump administration leaders encourage Americans to drop "fat" for "fit." The two squared off to notch 50 pullups and 100 pushups in under five minutes while surrounded by military members of the Navy and Marines, video first shared with Fox News Digital shows. "We had our big Pete and Bobby challenge today, 50 pull ups. 100 push-ups. You try to get under five minutes," Kennedy said while wearing his typical gym attire of jeans and a T-shirt. The challenge comes as Kennedy unleashes the "Make America Healthy Again" movement, which includes promoting that Americans eat whole foods versus processed meals, and Hegseth rallies the U.S. military to be the most fit and well-equipped to handle defending the nation. "Completely unacceptable," Hegseth posted on X in response to a headline declaring two-thirds of the military is overweght. "This is what happens when standards are IGNORED — and this is what we are changing. REAL fitness & weight standards are here. We will be FIT, not FAT." The pair squared-off to see who could beat the five-minute challenge, with Hegseth coming in just over the five-minute mark but defeating Kennedy. "We got close. I was about 5:25," Hegseth said in the video. "You were right behind me," he added referring to the HHS chief, who is 71 years old. Hegseth remarked that a few of the Marines in the gym at the time beat the challenge and came in under four minutes, while one other completed the challenge under three minutes. "It was President Trump who inspired us to do this," Kennedy said in the video shared with Fox Digital. "This is the beginning of our tour challenging Americans to get back in shape, eat better, but also, you need to get out and exercise." The pair also challenged another Cabinet member to join them in the competition: Secretary of Transportation Sean Duffy. "Secretary Duffy, you're invited to do the Pete and Bobby challenge. Can you do it in under five minutes? 50 pull-ups, 100 push-ups. What do you think?" Hegseth asked in the video as the pair chuckled. President Donald Trump has championed Kennedy's efforts encouraging Americans to cut out processed foods and get active through the MAHA movement, as well as repeatedly touting the U.S. military as "without a doubt the greatest fighting force in the history of the world" under Hegseth's leadership. At the youth level, Trump reinstated the Presidential Fitness Test and the President's Council on Sports, Fitness and Nutrition for American schoolchildren after former President Barack Obama retired it in favor of the Presidential Youth Fitness Program. Trump signed an executive order in July reestablishing the program and directed the council to launch "school-based programs that reward excellence in physical education and develop criteria for a Presidential Fitness Award." "Thank you, President Trump, for setting the example. Presidential physical fitness. Make America Healthy Again. Fit, not fat. We're going to have a war-fighting force, young men and women who are prepared to defend the nation. We're doing it as a team. Join us," Hegseth added in the video.
Yahoo
an hour ago
- Yahoo
ONWARD Medical Receives FDA IDE Approval to Initiate the Empower BP Pivotal Study with the ARC-IM System
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) The investigational device exemption (IDE) allows initiation of a global pivotal study designed to assess the safety and efficacy of the ARCIM System®, an implantable neurostimulation technology developed to address blood pressure instability after spinal cord injury (SCI). Managing blood pressure instability is a major unmet need after SCI, with a significant impact on cardiovascular health and quality of life. Approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe are expected to participate. EINDHOVEN, The Netherlands, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that the US Food and Drug Administration (FDA) has approved an investigational device exemption for the ARC-IM System. With this approval, the Company can initiate the Empower BP pivotal study to assess the safety and efficacy of its implantable spinal stimulation system to address blood pressure instability after SCI. Empower BP is the Company's second global pivotal study, and the first to evaluate the implantable ARC-IM System. The randomized, double-blinded, sham-controlled study is expected to involve approximately 20 leading neurorehabilitation and neurosurgical research centers across the US, Canada and Europe, with first patient enrollment anticipated before the end of the year. The study will target participants with injuries at spinal cord levels C2-T6, injury severities of AIS A-D, and blood pressure instability characterized by chronic orthostatic hypotension (OH) and episodes of autonomic dysreflexia (AD). 'This is an important milestone for ONWARD and the SCI community,' said Dave Marver, CEO of ONWARD. 'Our ARC-IM System is designed to address several unmet needs, including blood pressure instability which is a major recovery target after spinal cord injury. With this IDE approval, we continue to advance our innovation pipeline and inspire realistic hope in restoring autonomic functions and independence after SCI and other movement disabilities.' Over 50% of people with SCI experience blood pressure instability, affecting nearly 350,000 people in the US and Europe.1 Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and quality of life. The most frequent symptoms include dizziness, lightheadedness, blurred vision and fatigue.2 'Blood pressure instability, especially chronic low blood pressure, is one of the most hidden and unrecognized functional complications of spinal cord injury,' explains Dr. James Guest, neurosurgeon and Professor of Neurological Surgery at the University of Miami. 'It leaves people feeling unwell and can significantly impact their overall quality of life. Blood pressure instability also increases the risk of cardiovascular disease, making addressing this unmet need critical for improving the long-term outcomes of SCI.' The ONWARD ARC-IM System is an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation. It is the first neuroprosthetic system designed to manage blood pressure instability in people with SCI. It comprises the implanted ONWARD Neurostimulator (IPG) and the ARC-IM Thoracic Lead. The ARC-IM Thoracic Lead is optimized for surgical placement in a specific region of the thoracic spinal cord, called the 'Hemodynamic Hotspot'. The location was first discovered by the Company's research partners at the Swiss Federal Institute of Technology Lausanne (EPFL), Centre Hospitalier Universitaire Vaudois (CHUV), and the University of Calgary in a study published in Nature in January 2021.3 In December 2022, the Company announced positive top-line interim clinical results from its feasibility studies showing improved blood pressure regulation and improved hemodynamic stability after SCI. In addition to immediate and sustained improved blood pressure levels, participants taking anti-hypotension drugs prior to the study significantly reduced or discontinued their medication. Participants also reported improved general well-being and a reduction in orthostatic hypotension, including reduced dizziness and increased energy. Detailed interim results from these studies are expected to be published later this year. Managing blood pressure instability is among the major unmet needs for which the FDA has awarded the Company one of its 10 Breakthrough Device Designations. This award is reserved for novel, cutting-edge therapies addressing unmet needs and provides potential regulatory and reimbursement benefits. To stay informed about ONWARD's research studies, technologies, and the availability of therapies in your area, please complete this webform. About ONWARD Medical ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries, and other movement disabilities. Building on over a decade of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device designations from the FDA. The Company's ARC-EX® System is cleared for commercial sale in the US. The Company is also developing an investigational implantable system called ARC-IM, which can be paired with a brain-computer interface (BCI) to restore thought-driven movement. Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit For Media Inquiries: Sébastien Cros, VP Communications media@ For Investor Inquiries: investors@ Notes and references: 1. Katzelnick CG et al. Blood Pressure Instability in Persons With SCI: Evidence From a 30-Day Home Monitoring Observation. Am J Hypertens. 2019 Sep 24;32(10):938-944 2. Carlozzi, N. E. et al. Impact of blood pressure dysregulation on health-related quality of life in persons with spinal cord injury: development of a conceptual model. Arch. Phys. Med. Rehabil. 94, 1721–1730 (2013) 3. Squair, J.W. et al. Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature 590, 308–314 (2021) Forward-Looking Statements Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Prenatal Pesticide Exposure Alters Children's Brain Development, Impairing Motor Skills
Exposure during pregnancy to chlorpyrifos, a widely used pesticide, causes lasting changes in children's brains and motor function impairments. LOS ANGELES, August 18, 2025--(BUSINESS WIRE)--A joint observational study by Children's Hospital Los Angeles (CHLA) and Columbia University has found that prenatal exposure to a common pesticide also used as an insecticide could impair children's brain development and motor function for years to come. In this long-term study of children between 6 and 14 years old, followed since birth, prenatal exposure to the pesticide chlorpyrifos (CPF) was associated with alterations in brain structure and impairments in motor function. This is the first study to show that prenatal exposure to a pesticide produces enduring and widespread molecular, cellular, and metabolic effects in the brain. The results were published in JAMA Neurology. "More CPF exposure led to more thickening of the cerebral cortex—the area of the brain that directs functions like thinking, memory and movement," says Bradley Peterson, MD, first author on the study and Chief of the Division of Child & Adolescent Psychiatry at Children's Hospital, where he also leads the Brain Imaging Lab. "We don't know the consequences of these brain effects, but we found that CPF exposure most impairs motor functioning." Fetal exposure to CPF affects neurological development Between January 1998 and July 2005, the team conducted behavioral assessments and MRI scans of the brains of 270 youths in upper Manhattan whose mothers had been exposed to CPF during pregnancy when their apartments were fumigated. The researchers from CHLA and the Columbia University Mailman School of Public Health also accessed behavioral exposure information from umbilical cord samples from each child at delivery as well as samples of their mothers' blood collected the day after birth. The MRI scans found: Thickening of the brain cortex Alterations in white matter, which could affect brain function Changes in the internal capsule, the structure that governs communication between the cortex and subcortical areas, affect motor and sensory pathways Fewer neurons in white matter could signal impaired development Abnormalities in brain pathways that support motor control Impaired nerve insulation (myelination), which can affect function Reduced blood flow, indicating less energy use, throughout the brain "Current widespread exposures, at levels comparable to those experienced in this sample, continue to place farm workers, pregnant women, and unborn children in harm's way. It is vitally important that we continue to monitor the levels of exposure in potentially vulnerable populations, especially in pregnant women in agricultural communities, as their infants continue to be at risk," said Virginia Rauh, ScD, senior author on the study and the Jane and Alan Batkin Professor of Population and Family Health at Columbia Mailman School. The data strongly suggest that one of the fundamental problems of CPF exposure is altered differentiation of neuronal tissue, says Dr. Peterson. "That happens early in pregnancy, when neurons develop in the cortex and differentiate into cortical gray matter—densely packed nerve cells which process information—and underlying white matter—which is mostly nerve fibers that connect neurons," he says. "All these abnormalities can contribute to poor motor function in these kids. The contributing mechanisms seem to be the inflammation and oxidative stress that CPF and other pesticides produce." The researchers also found a dramatic and global reduction in brain blood flow. "To me, this is the most profound finding because it's so powerful and very rare to see something like this," says Dr. Peterson. "Blood flow is an important indicator of underlying metabolism—the energy used by brain tissue. In my opinion, it's maybe the most important finding of the paper, because it says that globally there's a problem with brain metabolism in direct proportion to how much CPF exposure they had." While this current paper reports results on children up to age 14, the researchers have now collected MRI scans of adolescents up to age 19 and are analyzing the data in preparation for the next release of results from this ongoing study. CPF is in the food chain CPF is an organophosphate pesticide—in the same chemical family as nerve gas–that disrupts nerve signaling. In pregnancy, it can cross the placenta to the fetus, easily traversing the fetal blood-brain barrier. Prior studies by other groups have linked maternal CPF exposure to lower birth weight, smaller head size, abnormal newborn reflexes, and neurodevelopmental issues in toddlers—including autism, inattention, and lower intelligence. CPF was banned from home use in the U.S. in 2001, but it is still used as an agricultural pesticide. A 2020 ban on food crops was reversed in 2023. The EPA wants to continue to allow CPF residues in certain food crops, including apples, strawberries, asparagus, tart cherries, citrus, and peaches. "It's in our food supply," cautions Dr. Peterson. "And other chemicals used in the home act in similar ways and almost certainly increase inflammation and oxidative stress. This is why it is important to do these studies about the chemicals in our environment to protect children's health." Editor's note: An embargoed copy of the study can be obtained from JAMA Neurology (mediarelations@ or CHLA can provide a copy. About Children's Hospital Los Angeles Children's Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Since its founding in 1901, CHLA has delivered a level of pediatric care that is among the best in the world. Ranked one of the top 10 children's hospitals in the nation by U.S. News & World Report, Children's Hospital Los Angeles provides comprehensive and compassionate care to one of the largest and most diverse pediatric patient populations in the country. The hospital is the top-ranked children's hospital in California and the Pacific U.S. region for 2024-25. A leader in pediatric research, CHLA is among the top 10 children's hospitals for research funding from the National Institutes of Health. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, translating scientific discoveries into life-changing treatments for patients around the globe. As a pediatric academic medical center, CHLA is also home to one of the largest graduate education programs for pediatricians in the United States. The hospital's commitment to building stronger, healthier communities is evident in CHLA's efforts to enhance health education and literacy, introduce more people to careers in health care, and fight food insecurity. To learn more, follow CHLA on Facebook, Instagram, LinkedIn, YouTube, and X, and visit View source version on Contacts CHLA Contact: Lorenzo Benet e: lbenet@ Sign in to access your portfolio
